EazeBio Information

EazeBio is real-time biological intelligence. A 5-minute test. Phone-scanned. 20+ biomarkers, read as a trajectory over time — not a one-time snapshot. No lab. No waiting room. No barrier. We exist because the system was built to react. To wait for the number to shift, for the symptom to appear, for the diagnosis to finally land — often years too late. We are building a different default: prediction, prevention, personalization. What we have built: • 200+ proprietary antibodies and 14 issued patents in biomarker chemistry and aptamer detection. • Three sensing modalities — lateral flow (LFA), fluorescence (FIA), and a next-generation cortisol biosensor co-developed with UC Santa Cruz and the University of Washington. • 75+ CE-marked panels across women's health, metabolic, mental clarity, cancer early detection, gut and immunity, and food safety. • An AI engine that reads biomarker trajectories and generates a personalized wellness report. Clinical evidence: AIIMS Bhopal pilot — 1,000 women, 36 villages, four biomarkers, >90% sensitivity and specificity. Presenting at ADLM 2026. Founded in 2024 by Reem Mahrat (CEO) and Ying Chen, PhD (CSO). 100% women-founded and women-led. Headquartered in Livermore, CA.